Biological Therapy for Psoriatic Arthritis: Current State and Future Perspectives

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2024 Sep 23

PMID 39311915

Authors

Dominika Boboryko

Joanna Olejnik-Wojciechowska

Magdalena Baranowska

Aleksandra Wiktoria Bratborska

Patryk Skorka

Andrzej Pawlik

Affiliations

Soon will be listed here.

Abstract

Psoriatic arthritis is a medical condition that lies at the intersection of various fields of medicine, and its therapy always requires a comprehensive, holistic approach. Biological disease-modifying antirheumatic drugs (bDMARDs) constitute an extremely effective treatment method for PsA, provided that appropriate principles for patient qualification for the drug are followed, along with subsequent monitoring of the response to treatment. Based on their mechanisms of action, four main groups of bDMARDs used in PsA can be distinguished (TNF inhibitors, IL-12/23 and IL-23 inhibitors, IL-17 inhibitors, CTLA4 agonists). Clinical trials are ongoing in search of registration for additional bDMARDs, and the tasks for doctors and scientists worldwide include patient education, increasing treatment accessibility, and optimizing its costs.

References

van de Kerkhof P . From Empirical to Pathogenesis-Based Treatments for Psoriasis. J Invest Dermatol. 2022; 142(7):1778-1785. DOI: 10.1016/j.jid.2022.01.014. View

Nestle F, Kaplan D, Barker J . Psoriasis. N Engl J Med. 2009; 361(5):496-509. DOI: 10.1056/NEJMra0804595. View

Su Y . Early diagnosis of psoriatic arthritis among psoriasis patients: clinical experience sharing. Clin Rheumatol. 2020; 39(12):3677-3684. PMC: 7648743. DOI: 10.1007/s10067-020-05132-1. View

Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H . Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54(8):2665-73. DOI: 10.1002/art.21972. View

Moll J, WRIGHT V . Psoriatic arthritis. Semin Arthritis Rheum. 1973; 3(1):55-78. DOI: 10.1016/0049-0172(73)90035-8. View

Chandran V, Gladman D, Helliwell P, Gudbjornsson B . Arthritis mutilans: a report from the GRAPPA 2012 annual meeting. J Rheumatol. 2013; 40(8):1419-22. DOI: 10.3899/jrheum.130453. View

Scher J, Ogdie A, Merola J, Ritchlin C . Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019; 15(3):153-166. DOI: 10.1038/s41584-019-0175-0. View

Yamaoka K, Oku K . JAK inhibitors in rheumatology. Immunol Med. 2023; 46(3):143-152. DOI: 10.1080/25785826.2023.2172808. View

Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M . JAK Inhibitors in Psoriatic Disease. Clin Cosmet Investig Dermatol. 2023; 16:3129-3145. PMC: 10625379. DOI: 10.2147/CCID.S433367. View

10.

Klein B, Treudler R, Simon J . . J Dtsch Dermatol Ges. 2022; 20(1):19-25. DOI: 10.1111/ddg.14668_g. View

11.

DAngelo S, Cantini F, Ramonda R, Cantarini L, Carletto A, Chimenti M . Effectiveness of Adalimumab for the Treatment of Psoriatic Arthritis: An Italian Real-Life Retrospective Study. Front Pharmacol. 2020; 10:1497. PMC: 6923751. DOI: 10.3389/fphar.2019.01497. View

12.

Sundanum S, Orr C, Veale D . Targeted Therapies in Psoriatic Arthritis-An Update. Int J Mol Sci. 2023; 24(7). PMC: 10094037. DOI: 10.3390/ijms24076384. View

13.

Paine A, Ritchlin C . Bone remodeling in psoriasis and psoriatic arthritis: an update. Curr Opin Rheumatol. 2015; 28(1):66-75. DOI: 10.1097/BOR.0000000000000232. View

14.

Mease P, Gladman D, Ritchlin C, Ruderman E, Steinfeld S, Choy E . Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005; 52(10):3279-89. DOI: 10.1002/art.21306. View

15.

Mease P, Kivitz A, Burch F, Siegel E, Cohen S, Ory P . Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004; 50(7):2264-72. DOI: 10.1002/art.20335. View

16.

Antoni C, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester G, Schneider U . Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005; 52(4):1227-36. DOI: 10.1002/art.20967. View

17.

Kavanaugh A, McInnes I, Mease P, Krueger G, Gladman D, Gomez-Reino J . Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009; 60(4):976-86. DOI: 10.1002/art.24403. View

18.

Mease P, Fleischmann R, Deodhar A, Wollenhaupt J, Khraishi M, Kielar D . Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Ann Rheum Dis. 2013; 73(1):48-55. PMC: 3888622. DOI: 10.1136/annrheumdis-2013-203696. View

19.

Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T . Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study. Semin Arthritis Rheum. 2016; 46(6):732-739. DOI: 10.1016/j.semarthrit.2016.09.005. View

20.

Gladman D, Mease P, Cifaldi M, Perdok R, Sasso E, Medich J . Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. Ann Rheum Dis. 2006; 66(2):163-8. PMC: 1798491. DOI: 10.1136/ard.2006.057901. View